Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response

Three-quarters of compounds that enter clinical trials fail to make it to market due to safety or efficacy concerns. This statistic strongly suggests a need for better screening methods that result in improved translatability of compounds during the preclinical testing period. Patient-derived organo...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiller, Erin R., Ung, Nolan, Kim, Seungil, Patsch, Katherin, Lau, Roy, Strelez, Carly, Doshi, Chirag, Choung, Sarah, Choi, Brandon, Juarez Rosales, Edwin Francisco, Lenz, Heinz-Josef, Matasci, Naim, Mumenthaler, Shannon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724556/
https://www.ncbi.nlm.nih.gov/pubmed/34993134
http://dx.doi.org/10.3389/fonc.2021.771173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724556/
https://www.ncbi.nlm.nih.gov/pubmed/34993134
http://dx.doi.org/10.3389/fonc.2021.771173

Ejemplares similares